Sarepta Therapeutics is reeling after a series of setbacks related to its gene therapy products, most notably Elevidys, designed for Duchenne muscular dystrophy. The company refused an FDA request to halt shipments of Elevidys, despite ongoing investigations into three patient deaths associated with its therapies, leading to a staggering 40% drop in its stock price. Following the reports of fatalities, the FDA is considering the withdrawal of Elevidys from the market and has placed several clinical trials on hold. In response to these challenges, Sarepta announced a significant restructuring plan, which includes laying off approximately 500 employees. These developments have caused significant distress among families affected by Duchenne muscular dystrophy, who fear that progress in treatment could be jeopardized.